- The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market.
- Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-themed ETFs.
- Some U.S. biotechnology stocks that IDNA holds have started generating positive returns, and the pharmaceutical stocks listed in global markets have always maintained a good return.
For further details see:
IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally